Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.

ABSTRACT:

Background

Angiogenesis inhibitors showed activity in ovarian cancer, but preliminary data could not accurately reflect the survival benefit. We thus did a systematic review and meta-analysis of randomized controlled trials to reassess the efficacy and safety of angiogenesis inhibitors combined with chemotherapy for ovarian cancer.

Methods

We searched PubMed, EMBASE, Cochrane, and ClinicalTrials.gov for randomized controlled trials comparing angiogenesis inhibitors containing therapy with conventional chemotherapy alone or no further treatment. Our main outcomes were the progression-free survival (PFS), overall survival (OS), and common adverse events.

Results

Fifteen trials were included (N = 8721 participants). For newly diagnosed ovarian cancer, combination treatme

SUBMITTER: Wang H 

PROVIDER: S-EPMC5976222 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature